Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately ...

The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...

Researchers sought to determine whether zanubrutinib would outperform acalabrutinib in an indirect treatment comparison in R/R CLL.

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton ...

Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, introduce themselves and give an overview of chronic lymphocytic leukemia (CLL), highlighting symptoms and patient presentation. Dr ...

Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for ...

Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...

Despite the clear improvement in the treatment of patients with CLL achieved during the past few years, there is still a subset of patients who are refractory to therapy. Resistance to purine analogs ...

“The consistent association between GP5 responses and ETD suggests the GP5’s ability to capture how well patients tolerate ...

Besides the presence or absence of specific genetic aberrations, several pieces of evidence point to a key role of the microenvironment in the survival of leukemic cells. CLL cells rapidly undergo ...